HilleVax (NASDAQ:HLVX) Stock Rating Lowered by Leerink Partnrs

Leerink Partnrs cut shares of HilleVax (NASDAQ:HLVX) from a strong-buy rating to a hold rating in a research note released on Tuesday morning, Zacks.com reports. Leerink Partnrs also issued estimates for HilleVax’s Q2 2024 earnings at ($0.82) EPS, Q3 2024 earnings at ($0.42) EPS, Q4 2024 earnings at ($0.26) EPS, FY2024 earnings at ($2.46) EPS, FY2025 earnings at ($2.17) EPS, FY2026 earnings at ($2.21) EPS and FY2027 earnings at ($1.42) EPS.

Other research analysts also recently issued reports about the company. SVB Leerink downgraded HilleVax from an outperform rating to a market perform rating and cut their price objective for the stock from $28.00 to $2.00 in a research report on Tuesday. Guggenheim downgraded HilleVax from a buy rating to a neutral rating in a research report on Monday. JPMorgan Chase & Co. restated a neutral rating and set a $5.00 price objective (down from $24.00) on shares of HilleVax in a research report on Monday. HC Wainwright restated a neutral rating and set a $2.00 price objective (down from $28.00) on shares of HilleVax in a research report on Tuesday. Finally, Stifel Nicolaus downgraded HilleVax from a buy rating to a hold rating and cut their price objective for the stock from $34.00 to $3.00 in a research report on Tuesday. Six research analysts have rated the stock with a hold rating, Based on data from MarketBeat, HilleVax has a consensus rating of Hold and a consensus price target of $9.20.

HilleVax Price Performance

Shares of NASDAQ:HLVX opened at $1.67 on Tuesday. The business’s 50 day simple moving average is $12.80 and its 200-day simple moving average is $14.50. The firm has a market capitalization of $83.03 million, a price-to-earnings ratio of -0.51 and a beta of 0.78. The company has a debt-to-equity ratio of 0.11, a current ratio of 10.92 and a quick ratio of 10.92. HilleVax has a 12 month low of $1.55 and a 12 month high of $20.22.

HilleVax (NASDAQ:HLVX) last announced its quarterly earnings results on Thursday, May 9th. The company reported ($0.97) EPS for the quarter, missing the consensus estimate of ($0.84) by ($0.13). As a group, equities analysts forecast that HilleVax will post -3.14 earnings per share for the current fiscal year.

Insider Buying and Selling at HilleVax

In other HilleVax news, Director Aditya Kohli sold 6,000 shares of the business’s stock in a transaction on Monday, May 20th. The stock was sold at an average price of $15.45, for a total value of $92,700.00. Following the completion of the transaction, the director now directly owns 776,878 shares in the company, valued at approximately $12,002,765.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last three months, insiders sold 12,898 shares of company stock worth $193,766. Insiders own 71.10% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of HLVX. EntryPoint Capital LLC acquired a new position in HilleVax in the 1st quarter valued at $80,000. SG Americas Securities LLC acquired a new position in HilleVax in the 4th quarter valued at $139,000. Tidal Investments LLC acquired a new position in HilleVax in the 1st quarter valued at $207,000. abrdn plc purchased a new stake in shares of HilleVax during the 4th quarter valued at $433,000. Finally, Swiss National Bank grew its stake in shares of HilleVax by 22.4% during the 4th quarter. Swiss National Bank now owns 38,200 shares of the company’s stock valued at $613,000 after buying an additional 7,000 shares during the period. 86.42% of the stock is currently owned by institutional investors and hedge funds.

About HilleVax

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.